US 11,866,742 B2
Fusion proteins comprising enzyme replacement therapy enzymes
Anastasia Henry, South San Francisco, CA (US); Mihalis S. Kariolis, San Mateo, CA (US); Cathal S. Mahon, San Francisco, CA (US); Adam P. Silverman, San Carlos, CA (US); Ankita Srivastava, South San Francisco, CA (US); and Julie Ullman, San Francisco, CA (US)
Assigned to DENALI THERAPEUTICS INC., South San Francisco, CA (US)
Filed by Denali Therapeutics Inc., South San Francisco, CA (US)
Filed on Nov. 23, 2020, as Appl. No. 17/102,138.
Application 17/102,138 is a division of application No. 16/355,339, filed on Mar. 15, 2019, granted, now 10,870,837, issued on Dec. 22, 2020.
Application 16/355,339 is a continuation of application No. PCT/US2018/053747, filed on Oct. 1, 2018.
Claims priority of provisional application 62/721,396, filed on Aug. 22, 2018.
Claims priority of provisional application 62/678,183, filed on May 30, 2018.
Claims priority of provisional application 62/626,365, filed on Feb. 5, 2018.
Claims priority of provisional application 62/583,276, filed on Nov. 8, 2017.
Claims priority of provisional application 62/566,898, filed on Oct. 2, 2017.
Prior Publication US 2021/0198640 A1, Jul. 1, 2021
Int. Cl. A61K 38/43 (2006.01); C12N 9/16 (2006.01); C07K 14/00 (2006.01); A61K 47/68 (2017.01); C07K 19/00 (2006.01); C12N 15/62 (2006.01); C07K 16/28 (2006.01); C12N 9/18 (2006.01); C12N 9/24 (2006.01); A61K 38/00 (2006.01)
CPC C12N 9/16 (2013.01) [A61K 47/68 (2017.08); C07K 14/00 (2013.01); C07K 16/28 (2013.01); C07K 16/2881 (2013.01); C07K 19/00 (2013.01); C12N 9/18 (2013.01); C12N 9/2402 (2013.01); C12N 15/62 (2013.01); C12Y 301/06013 (2013.01); A61K 38/00 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2319/30 (2013.01); C12Y 301/04012 (2013.01); C12Y 302/01045 (2013.01); C12Y 310/01001 (2013.01)] 35 Claims
 
1. A method of treating Hunter syndrome in a subject in need thereof, comprising administering to the subject a protein comprising:
a. a fusion polypeptide comprising a first Fc polypeptide linked to an iduronate 2-sulfatase (IDS) amino acid sequence, wherein the IDS amino acid sequence comprises a sequence having at least 90% identity to SEQ ID NO: 92, and wherein the IDS amino acid sequence is linked to the N-terminus of the first Fc polypeptide; and
b. a second Fc polypeptide comprising a sequence having at least 90% identity to SEQ ID NO: 151 that is capable of specifically binding to a transferrin receptor.